Our leadership
Learn more
Joel helps life sciences companies structure the intellectual property transactions that shape their futures. His clients trust him with their most consequential partnering matters: complex collaborations, licenses, and strategic alliances that often represent bet-the-company decisions. He works with companies at every stage, from start-ups through mature businesses, and his practice spans the full lifecycle, from formation through late-stage financing and M&A.
Experience
Representative matters
Representative matters
Advised Go Therapeutics on a strategic collaboration, option, and license agreement with Astellas to develop novel antibodies for immuno-oncology, with a potential deal value of $783.5 million plus royalties.
Counseled QurAlis on a license and collaboration with Lilly for a potentially best-in-class therapy for neurodegenerative diseases, including ALS and frontotemporal dementia, with a potential deal value of $622 million plus royalties.
Represented Muna in a strategic alliance with GSK to accelerate development of novel treatments for Alzheimer’s disease, with a potential deal value of €733.5 million plus royalties.
Representative Experience
Advised Go Therapeutics on a strategic collaboration, option, and license agreement with Astellas to develop novel antibodies for immuno-oncology, with a potential deal value of $783.5 million plus royalties.
Counseled QurAlis on a license and collaboration with Lilly for a potentially best-in-class therapy for neurodegenerative diseases, including ALS and frontotemporal dementia, with a potential deal value of $622 million plus royalties.
Represented Muna in a strategic alliance with GSK to accelerate development of novel treatments for Alzheimer’s disease, with a potential deal value of €733.5 million plus royalties.
Counseled IMMvention on a strategic collaboration with Novo Nordisk to develop oral therapies for sickle cell disease and other chronic diseases, with a potential deal value of $173 million.
Represented Photys in a research collaboration with Novo Nordisk to develop novel treatments for cardiometabolic diseases, with a potential deal value of $186 million plus royalties.
Advised Moonwalk on a collaboration with NVIDIA to develop AI models for target identification and validation in drug research and development.
Structured a joint venture between Overland and ADC Therapeutics to advance development of ZYNLONTA® for treatment of relapsed or refractory diffuse large B-cell lymphoma.
Represented Overland in forming a joint venture with Allogene Therapeutics for the development of allogeneic CAR T cell therapy products for cancer.
Negotiated foundational intellectual property in-licenses from leading academic and research institutions, including Harvard, Massachusetts Institute of Technology, Broad Institute, Wyss Institute, Massachusetts General Hospital, Brigham and Women’s Hospital, Boston Children’s Hospital, Howard Hughes Medical Institute, Whitehead Institute, University of Massachusetts Dartmouth, Yale, Cornell, University of Pennsylvania, Children’s Hospital of Philadelphia, Johns Hopkins, Stanford, University of California, Seattle Children’s Hospital, Colorado State University, University of Iowa, University of Southern California, and others.
Recognitions
Recognized by LMG Life Sciences as the U.S. Rising Star, Financial and Corporate, at the 2025 Life Sciences Americas Awards
Credentials
Education
Education
- Georgetown University Law Center, J.D.
- Princeton University, B.S.E., Computer Science
Professional admissions & qualifications
Professional admissions & qualifications
- Massachusetts